Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. PPBT
PPBT logo

PPBT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.560
Open
4.540
VWAP
4.40
Vol
14.54K
Mkt Cap
4.10M
Low
4.100
Amount
63.98K
EV/EBITDA(TTM)
--
Total Shares
903.04K
EV
-4.15M
EV/OCF(TTM)
--
P/S(TTM)
--
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Show More

Events Timeline

(ET)
2026-02-27
19:50:00
Purple Biotech Trading Halted, News Pending
select
2026-02-25 (ET)
2026-02-25
17:40:00
Purple Biotech Adjusts ADS Ratio to 1:2000
select
2026-01-07 (ET)
2026-01-07
08:10:00
Purple Biotech Completes Toxicology Study of IM1240
select
2025-12-11 (ET)
2025-12-11
07:30:00
Purple Biotech Reports Positive Preclinical Data from CAPTN-3 Antibody Platform
select
2025-11-14 (ET)
2025-11-14
08:07:49
Purple Biotech anticipates funding to last until the first half of 2027.
select
2025-11-14
08:07:12
Purple Biotech Announces Q3 Earnings Per Share of 29 Cents Compared to 39 Cents Last Year
select
2025-10-29 (ET)
2025-10-29
07:38:18
Purple Biotech Reaches Key Manufacturing Milestone for IM1240
select
2025-10-20 (ET)
2025-10-20
16:01:52
Purple Biotech Gets Nasdaq Noncompliance Notice
select
2025-09-10 (ET)
2025-09-10
08:07:51
Purple Biotech anticipates European patent approval for NT219
select
2025-09-04 (ET)
2025-09-04
09:19:49
Purple Biotech sets public offering price at $1.00 for 5.99 million ADSs
select

News

Newsfilter
8.5
02-25Newsfilter
Purple Biotech Adjusts ADS Ratio to Meet Nasdaq Compliance
  • ADS Ratio Change: Purple Biotech announced a change in the ADS ratio from 1:200 to 1:2000, effective March 2, 2026, aimed at meeting Nasdaq's compliance requirement for a minimum bid price of $1.00, thus mitigating delisting risks.
  • Reverse Split Impact: The ADS ratio change effectively acts as a one-for-ten reverse split, which, while not affecting the company's ordinary shares, is expected to increase the trading price of the ADSs, enhancing their suitability for trading on Nasdaq.
  • Simplified Holder Actions: Registered holders of certificated ADSs will be required to surrender their ADSs to the depositary bank for cancellation, while holders of uncertificated ADSs will have their shares automatically exchanged, reducing operational complexity for investors.
  • Future Growth Potential: With a focus on developing innovative immunotherapies, the ADS ratio change is anticipated to attract more investor interest in Purple Biotech's clinical-stage cancer products, further strengthening the company's market position in tumor immunotherapy.
Globenewswire
3.5
2025-12-11Globenewswire
Purple Biotech Reports Significant Anti-Tumor Activity of CAPTN-3 Platform at ESMO IO 2025
  • Significant Anti-Tumor Activity: Purple Biotech's CAPTN-3 platform demonstrates substantial anti-tumor activity through its tri-specific antibodies IM1240 and IM1305 across different tumor antigens, particularly showing strong efficacy in PD-1 resistant models, indicating the platform's potential applicability in various solid tumors.
  • Key Role of NKG2A Arm: Transcriptomic analysis of approximately 11,000 TCGA samples reveals a strong correlation between NKG2A expression and tumor expression of 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs, which enhances anti-cancer immune activity, especially in PD-1 resistant patient-derived samples.
  • Platform Adaptability Validation: The new candidate IM1305, targeting TROP2, shows high-affinity binding (EC₅₀ ~2 nM) and potent PBMC-mediated tumor cell killing across multiple tumor types, further validating the adaptability and broad application potential of the CAPTN-3 platform, particularly in triple-negative breast cancer.
  • Future Development Roadmap: Purple Biotech plans to advance CAPTN-3 toward IND-enabling studies in 2026, demonstrating the company's strategic commitment to addressing tumor immune evasion and drug resistance, aiming to capture market opportunities through continuous innovation.
Newsfilter
3.5
2025-12-11Newsfilter
Purple Biotech Reports New Anti-Tumor Data from CAPTN-3 Platform
  • Significant Anti-Tumor Activity: Purple Biotech's CAPTN-3 platform demonstrates substantial anti-tumor activity through its tri-specific antibodies IM1240 and IM1305 across different tumor antigens, particularly showing strong apoptosis induction in PD-1 resistant models, indicating the platform's potential applicability in various solid tumors.
  • Key Role of NKG2A Arm: Transcriptomic analysis of approximately 11,000 TCGA samples reveals a strong correlation between NKG2A expression and the expression of tumor antigens 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs, thereby enhancing anti-cancer immune activity, especially in PD-1 resistant patient-derived samples.
  • Platform Adaptability Validation: The new candidate IM1305 exhibits high affinity binding to both TROP2 and NKG2A, achieving potent tumor cell killing at low concentrations (EC₅₀ 1-5 pM) across multiple tumor types, further validating the adaptability and broad application potential of the CAPTN-3 platform.
  • Future Development Roadmap: Purple Biotech plans to advance the CAPTN-3 platform toward IND-enabling studies in 2026, with CEO Gil Efron emphasizing that the platform's multifunctional mechanisms will help overcome immune evasion challenges in solid tumor treatments, showcasing strong market prospects.
TipRanks
2.0
2025-10-30TipRanks
Three Penny Stocks to Keep an Eye on as of October 30, 2025
  • Penny Stocks to Watch: Cambium Networks, Purple Biotech, and Ernexa Therapeutics are highlighted as top penny stocks to monitor on October 30, 2025, based on their significant Dollar Volume and stock price movements.

  • Cambium Networks: The company experienced a Dollar Volume of $1.54 billion and a stock price increase of 377% following its integration with SpaceX's Starlink, enhancing its telecommunications solutions.

  • Purple Biotech: This clinical-stage biopharmaceutical company saw a Dollar Volume of $438.91 million and an 81% stock price surge after announcing a production milestone for its cancer treatment antibody, IM1240.

  • Ernexa Therapeutics: With a Dollar Volume of $375.25 million and a nearly 41% stock price rise, Ernexa is advancing its lead cell therapy for ovarian cancer through a partnership with Cellipont Bioservices.

Benzinga
9.5
2025-10-30Benzinga
Alphabet Shares Rise Approximately 8%; Check Out 20 Stocks Making Moves in Premarket Trading
  • Alphabet Inc. Financial Results: Alphabet Inc. reported third-quarter revenue of $102.35 billion and earnings of $2.87 per share, both exceeding analyst expectations, leading to a 7.8% increase in share price during pre-market trading.

  • Pre-Market Stock Gainers: Several stocks saw significant gains in pre-market trading, including VCI Global Limited (+110%), Cambium Networks Corporation (+87.8%), and Guardant Health, Inc. (+22.3%), following positive financial announcements.

  • Pre-Market Stock Losers: Notable declines were observed in stocks such as CERo Therapeutics Holdings, which fell 75.8% due to a Nasdaq delisting determination, and Aditxt, which dropped 38.8% after announcing a reverse stock split.

  • Market Overview: The article highlights various stocks' performance in pre-market trading, showcasing both significant gainers and losers, reflecting the volatility and reactions to recent financial results and announcements.

Benzinga
4.5
2025-10-29Benzinga
Dow Rises by 250 Points; Verizon Reports Mixed Results for Q3
  • U.S. Stock Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining approximately 250 points, while the NASDAQ and S&P 500 also saw increases of 0.65% and 0.33%, respectively.

  • Sector Movements: Information technology stocks experienced a significant rise of 1.4%, whereas real estate stocks fell by 1.1% during trading.

  • Verizon's Financial Results: Verizon Communications reported mixed third-quarter results, with a 1.5% year-over-year revenue growth of $33.8 billion, falling short of analyst expectations, but exceeding EPS estimates.

  • Notable Stock Movements: Cambium Networks' shares surged 209% after a significant announcement, while Advent Technologies saw a 51% drop in its stock price following disappointing guidance.

Wall Street analysts forecast PPBT stock price to rise
1 Analyst Rating
Wall Street analysts forecast PPBT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
34.00
Averages
34.00
High
34.00
Current: 0.000
sliders
Low
34.00
Averages
34.00
High
34.00
No data

No data

Valuation Metrics

The current forward P/E ratio for Purple Biotech Ltd (PPBT.O) is -0.39, compared to its 5-year average forward P/E of -6.66. For a more detailed relative valuation and DCF analysis to assess Purple Biotech Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.66
Current PE
-0.39
Overvalued PE
15.12
Undervalued PE
-28.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.32
Current PS
0.00
Overvalued PS
4.27
Undervalued PS
-1.63

Financials

AI Analysis
Annual
Quarterly

Whales Holding PPBT

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Purple Biotech Ltd (PPBT) stock price today?

The current price of PPBT is 4.54 USD — it has decreased -4.92

What is Purple Biotech Ltd (PPBT)'s business?

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

What is the price predicton of PPBT Stock?

Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Purple Biotech Ltd (PPBT)'s revenue for the last quarter?

Purple Biotech Ltd revenue for the last quarter amounts to -1.37M USD, decreased -35.91

What is Purple Biotech Ltd (PPBT)'s earnings per share (EPS) for the last quarter?

Purple Biotech Ltd. EPS for the last quarter amounts to -1004000.00 USD, decreased -68.93

How many employees does Purple Biotech Ltd (PPBT). have?

Purple Biotech Ltd (PPBT) has 9 emplpoyees as of March 10 2026.

What is Purple Biotech Ltd (PPBT) market cap?

Today PPBT has the market capitalization of 4.10M USD.